Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | NAMPT | P43490 | 17/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11616834 | 0.84 | HTT (1.00) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL4797277 | 0.84 | NPC1 (0.62) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL18317377 | 0.83 | NAMPT (0.75) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL4717429 | 0.82 | KMT2A (0.71) | NAMPT | |
| SCHEMBL4717455 | 0.81 | MDM2 (0.76) | HTT | |
| SCHEMBL14324426 | 0.81 | NAMPT (0.73) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL11615956 | 0.81 | NAMPT (0.84) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL11747002 | 0.81 | NAMPT (0.73) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL11748446 | 0.81 | NAMPT (0.73) | HTTNAMPTROCK2ROCK1 | |
| SCHEMBL8212768 | 0.81 | NAMPT (0.84) | HTTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002070519-A1 | MONOBACTAMS AS CATHEPSIN K INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | HTT 4018/4885NAMPT 1077/4885ROCK2 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.